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Background. Chest radiographs (CXRs) are frequently used to assess pneumonia cases. Variations in CXR appearances between 
epidemiological settings and their correlation with clinical signs are not well documented.
Methods. The Pneumonia Etiology Research for Child Health project enrolled 4232 cases of hospitalized World Health 
Organization (WHO)–defined severe and very severe pneumonia from 9 sites in 7 countries (Bangladesh, the Gambia, Kenya, Mali, 
South Africa, Thailand, and Zambia). At admission, each case underwent a standardized assessment of clinical signs and pneumonia 
risk factors by trained health personnel, and a CXR was taken that was interpreted using the standardized WHO methodology. CXRs 
were categorized as abnormal (consolidation and/or other infiltrate), normal, or uninterpretable.
Results. CXRs were interpretable in 3587 (85%) cases, of which 1935 (54%) were abnormal (site range, 35%–64%). Cases with 
abnormal CXRs were more likely than those with normal CXRs to have hypoxemia (45% vs 26%), crackles (69% vs 62%), tachypnea 
(85% vs 80%), or fever (20% vs 16%) and less likely to have wheeze (30% vs 38%; all P < .05). CXR consolidation was associated with 
a higher case fatality ratio at 30-day follow-up (13.5%) compared to other infiltrate (4.7%) or normal (4.9%) CXRs.
Conclusions. Clinically diagnosed pneumonia cases with abnormal CXRs were more likely to have signs typically associated 
with pneumonia. However, CXR-normal cases were common, and clinical signs considered indicative of pneumonia were present in 
substantial proportions of these cases. CXR-consolidation cases represent a group with an increased likelihood of death at 30 days 
post-discharge.
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The diagnosis of pneumonia in children is challenging because 
there is no single method with high sensitivity and high 
specificity [1, 2]. Clinical assessments for diagnosing pneu-
monia are sensitive but nonspecific, resulting in the inclusion 
of many nonpneumonia cases [3–5]. The use of chest radio-
graphs (CXRs) to identify pneumonia cases is also imperfect 
but understood to identify fewer false-positive cases, especially 
for Haemophilus influenzae type b (Hib) and Streptococcus 
pneumoniae disease [6, 7]. How accurately standardized CXR 
definitions correlate to clinical signs and risk factors for pneu-
monia is less well described, especially in differing geographic 
areas where the predominant pathogens can vary. We aimed to 
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describe the CXR findings of clinically diagnosed pneumonia 
cases in the Pneumonia Etiology Research for Child Health 
(PERCH) study and determine if there were differences in find-
ings by geography, epidemiological setting, particular clinical 
signs, or pneumonia risk factors.
METHODS
Data Collection
The PERCH study is a multicountry, standardized, case-control 
study of the causes and risk factors of childhood pneumonia. 
Nine study sites were located in 7 countries: Dhaka and Matlab, 
Bangladesh; Basse, the Gambia; Kilifi, Kenya; Bamako, Mali; 
Soweto, South Africa; Nakhon Phanom and Sa Kaeo, Thailand; 
and Lusaka, Zambia. These sites include the geographic regions 
where the vast majority of severe and fatal pneumonia cases occur 
and represent a diverse range of epidemiological contexts [8].
Cases were hospitalized children aged 1–59  months with 
World Health Organization (WHO)–defined severe or very 
severe pneumonia [5, 9]. Severe pneumonia was defined as hav-
ing cough and/or difficulty in breathing and lower chest wall 
indrawing. Very severe pneumonia was defined as cough and/
or difficulty in breathing and at least 1 of the following “dan-
ger signs”: central cyanosis, difficulty breastfeeding/drinking, 
vomiting everything, convulsions, lethargy, unconsciousness, 
or head nodding. Case exclusion criteria were hospitaliza-
tion within the previous 14 days, having been discharged as a 
PERCH case within the past 30 days, not residing in the study 
catchment area, or resolution of lower chest wall indrawing 
following bronchodilator therapy for those with severe pneu-
monia and wheeze. Standardization of clinical procedures used 
for participant enrollment and collection of PERCH data was 
achieved and maintained through on-site training for health-
worker personnel, the use of a training website and training 
materials, and intermittent evaluations and competency assess-
ments throughout the study [10].
A CXR was obtained from each case as soon as possible after 
clinical evaluation and study enrollment. All sites underwent 
a prestudy assessment of radiography facilities and procedures 
to review quality and safety and to standardize the collection 
of CXRs. Most sites used digital CXR imaging equipment, 
except Zambia and Matlab where analog techniques were used; 
analog images were scanned into digital format and all files 
managed according to a standardized operating procedure. 
Standardized methods for the collection and interpretation of 
chest radiographs are detailed elsewhere [11]. Each CXR was 
randomly assigned to be assessed by 2 members of a reading 
panel, comprised of 14 radiologists and pediatricians from 
study sites trained in the WHO methodology for the stand-
ardized interpretation of pediatric CXRs [7]. Two randomly 
selected members of a 4-person arbitration panel, consisting 
of experienced radiologists, resolved discordant interpreta-
tions by further blinded interpretations and a final consensus 
discussion if needed. Readers and arbitrators were unaware of 
the clinical and demographic information associated with each 
CXR, and readers did not interpret CXRs from their own site. 
Conclusions for CXRs were (1) consolidation (ie, alveolar con-
solidation, including pleural effusion if present) only; (2) other 
infiltrate only; (3) both consolidation and other infiltrate; (4) 
normal (no consolidation or infiltrate); and (5) uninterpretable 
for consolidation and/or other infiltrate. Additional conclusions 
derived from these 5 categories were (a) abnormal (1, 2, or 3), 
(b) any consolidation (1 or 3), and (c) any other infiltrate (2 
or 3). For cases with multiple CXRs, the conclusion of the first 
interpretable CXR was used. CXR conclusions were excluded if 
the CXR was taken more than 72 hours after admission to avoid 
bias from possible nosocomial complications.
Analyses
Results from the 2 Thailand sites were combined because they 
had similar epidemiologic and demographic characteristics. 
Results from sites with a high prevalence of human immuno-
deficiency virus (HIV) infection (South Africa and Zambia) 
were stratified by HIV status where relevant. HIV status was 
assumed to be negative for 385 cases where HIV status was 
unknown (HIV testing was not performed and/or there was no 
record of the child’s HIV history or maternal HIV history). Age 
was categorized as 1–5 months, 6–11 months, 12–23 months, 
and 24–59  months. Vaccination status was defined based on 
the number of doses a child received and the age at first dose 
or age at vaccine introduction in the community. Complete 
vaccination for pneumococcal conjugate vaccine was defined 
as 3 or more doses, or as 2 doses if there was at least 8 weeks 
between doses and the child was aged <9  months at enroll-
ment or >12 months at the time of the first dose, or 1 or more 
doses if the age at any of the doses, or age at introduction, was 
≥24 months. Complete vaccination for Hib conjugate vaccine 
was defined as 3 or more doses, or 1 or more doses for a child 
aged >12  months at first dose. Antibiotic pretreatment was 
defined by having either a positive serum bioassay or docu-
mented administration of antibiotics on the day of admission at 
the referral or study hospital prior to blood culture collection. 
Severe malnutrition was defined as a weight-for-age z score less 
than −3 below the median of the WHO child growth standards 
(WHO Anthro, version 3.2.2, January 2011). Moderate malnu-
trition was defined as a z score between −3 and −2 below the 
median of the WHO child growth standards. Tachypnea was 
defined as a respiratory rate ≥60 breaths per minute for chil-
dren aged <2 months, ≥50 for children 2–11 months, and ≥40 
for children 12–59  months. Tachycardia was defined as >160 
beats per minute (bpm) for children aged 1–11 months, >150 
bpm for children 12–35  months, and >140 bpm for children 
36–59 months. Hypoxemia at admission was defined as either 
a room air pulse oximetry reading of <90% at the 2 sites at ele-
vation (Zambia and South Africa) or <92% at all other sites or 
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as a child treated with supplemental oxygen on admission but 
without a room air pulse oximetry reading. Nonpneumonia 
admission diagnoses were recorded.
Analyses were restricted to cases with interpretable CXRs. 
Distributions of categorical variables were compared using the 
Pearson χ2 statistic. Logistic regression was used to estimate 
odds ratios of CXR outcomes for predictors of clinical signs 
and risk factors, first in univariate models stratified by site to 
evaluate heterogeneity, and then overall adjusted for site, age, 
pneumonia severity, and HIV status. To assess the independ-
ent effects of variables potentially correlated with each other, 
such as findings on clinical examination (eg, tachypnea and 
hypoxemia) or nonpneumonia admission diagnoses (eg, bron-
chiolitis and asthma), multivariable logistic regression models 
were examined including all variables for danger signs and 
clinical signs (for very severe cases), clinical signs, and admis-
sion diagnoses. Analyses were completed using Stata 12.1 (Stata 
Corporation, College Station, Texas).
Ethical Considerations
The institutional review board or ethical review committee at 
each study site institution and at the Johns Hopkins Bloomberg 
School of Public Health approved the PERCH study proto-
col. Parents or guardians of all participants provided written 
informed consent.
RESULTS
A total of 3973/4232 (94%) cases had a CXR conclusion and 
of these 386 (10%) were uninterpretable (range, 4% in Gambia 
and Thailand to 20% in Zambia), leaving 3587 cases for analyses 
(Figure 1). Overall, 54% of interpretable CXRs were abnormal 
(site range from 35% in Matlab to 64% in HIV-negative cases 
from South Africa; Figure  2 and Table  1). Of these, 50% had 
consolidation (either alone or with other infiltrate) and 50% 
had other infiltrate only. Those with abnormal CXRs were more 
likely to be HIV infected (19% vs 5%) and aged <24  months 
(88% vs 83%; Table 1). However, the relationship between age 
and CXR outcome differed by severity strata. Among severe 
pneumonia cases, the youngest children (aged 1–5  months) 
were less likely to have an abnormal CXR compared to those in 
older age categories, and among very severe pneumonia cases, 
the youngest children were more likely to have an abnormal 
CXR (Supplemental Table 1).
We evaluated differences between cases with abnormal and 
normal CXRs to assess the likelihood that those with normal 
CXRs truly had pneumonia. Cases with abnormal CXRs were 
significantly more likely to have central cyanosis, tachypnea, 
hypoxemia, crackles, nasal flaring, or temperature ≥38.5°C and 
were less likely to have vomiting, convulsions, or wheeze than 
cases with normal CXRs (all P ≤ .001; Table 1). Results were 
similar after controlling for site, age, pneumonia severity, and 
HIV (Supplemental Table 2). Cases with moderate and severe 
malnutrition, as measured by weight-for-age, had higher odds 
of an abnormal CXR compared to those without malnutrition 
(Supplemental Table 2). Despite these statistically significant dif-
ferences, high proportions of the 1652 CXR-normal cases had 
clinical signs generally considered more indicative of pneumonia 
(Table 1), including crackles (62%), nasal flaring (54%), hypox-
emia (26%), grunting (17%), and head nodding (14%). CXR-
normal cases had a mean of 1.7 of these signs, with 858/1652 
Figure 1. Flow diagram of case enrollment, chest radiograph (CXR) conclusions, and CXR status stratified by 30-day follow-up findings.
Downloaded from https://academic.oup.com/cid/article-abstract/64/suppl_3/S262/3858217
by London School of Hygiene & Tropical Medicine user
on 26 January 2018
Epidemiology of CXRs in Pneumonia • CID 2017:64 (Suppl 3) • S265
(52%) cases having 2 or more signs, including 266/1652 (16%) 
cases who had crackles and hypoxemia. These signs were absent 
in 243/1652 (15%) CXR-normal cases compared to 129/1935 
(7%) abnormal CXR cases. Results were similar when the 631 
cases with wheezing were excluded (Supplemental Table 3).
We investigated the independent association of clinical signs 
and admission diagnoses with CXR findings using logistic 
regression models adjusted for multiple covariates. The follow-
ing 3 groups of variables likely to show collinearity were iden-
tified: clinical signs among all cases, clinical and danger signs 
among very severe cases, and admission diagnoses. To assess 
independent effects of variables within each group, we included 
all variables for each group in a regression model and adjusted 
for site, age, severity, and HIV status (Table 2). For clinical signs 
among all cases, tachypnea, hypoxemia, crackles, and fever were 
all independently associated with an abnormal CXR, while 
wheeze was associated with a normal CXR (all P < .01). Among 
admission diagnoses, meningitis, bronchiolitis, gastroenteritis, 
and asthma were independently associated with a normal CXR; 
developmental delay was associated with an abnormal CXR; 
and the odds of having consolidation compared to a normal 
CXR were lower if admitted with a diagnosis of bronchiolitis, 
gastroenteritis, or meningitis (all P < .05). Among very severe 
cases, the only danger sign independently significantly associ-
ated with a CXR finding was convulsions, which showed lower 
odds of an abnormal CXR (odds ratio, 0.49; 95% confidence 
interval, 0.31–0.77). However, 58/203 (29%) cases with con-
vulsions and 1/10 (10%) cases with convulsions alone did have 
an abnormal CXR. Respiratory signs (hypoxemia, nasal flaring, 
tachypnea, and crackles) were all associated with an abnormal 
CXR among very severe cases (all P < .01).
We assessed the relationship between CXR findings and mor-
tality (Figure 1 and Table 3). Those who died and had an inter-
pretable CXR were twice as likely to have findings of consolidation 
(50% vs 24%) and less likely to have other infiltrates only (18% 
vs 28%) compared to those who survived. Of 3208 cases with an 
interpretable CXR and documented 30-day survival status, 837 
(26%) had a CXR finding of any consolidation of which 113 died 
(case fatality ratio [CFR], 13.5%) compared to 874 cases with other 
infiltrate only among whom there were 41 deaths (CFR, 4.7%) 
and 1497 cases that were CXR-normal among whom there were 
73 deaths (CFR, 4.9%; Table 3). These trends were similar when 
stratified by age (<12 months and ≥12 months; data not shown).
DISCUSSION
The PERCH study allows for a comprehensive assessment of the 
association between clinical characteristics and CXR findings 
in childhood pneumonia cases under highly standardized clin-
ical and radiographic interpretation conditions. We found that 
at the time of admission, those with WHO-defined severe or 
very severe pneumonia who had tachypnea, hypoxemia, crack-
les, or fever were more likely to have an abnormal CXR than 
those who did not have these findings, irrespective of other 
clinical signs. In contrast, those with convulsions or wheeze 
were less likely than those without these findings to have an 
abnormal CXR. These findings provide evidence that PERCH 
analyses restricted to cases with abnormal CXRs largely repre-
sent true pneumonia cases. CXR-normal cases likely include 
some children who have true pneumonia, as suggested by the 
52% of these cases who had 2 or more findings of hypoxemia, 
crackles, head nodding, nasal flaring, or grunting; however, it is 
difficult to distinguish with certainty which of these cases have 
pneumonia and which do not. Thus, as expected, standardized 
CXR definitions for epidemiological studies have limited pre-
dictive value for clinical care because a substantial proportion 
of children with a normal CXR finding also have clinical signs 
or risk factors indicative of pneumonia.
The categorization of CXRs in this study followed an estab-
lished methodology developed by the WHO for use in bacterial 
vaccine trials [7]. Previous evidence on correlations between 
clinical signs and radiological findings is mixed and compari-
sons are difficult because of varied definitions of “radiological 
pneumonia.” Some studies showed that tachypnea [12], hypox-
emia [13], and crackles [14] on admission may be predictive 
of radiological pneumonia, while others found clinical signs to 
be poor predictors of radiographic findings [15, 16]. A recent 
metaanalysis indicated that no single clinical feature is sufficient 
to predict radiological pneumonia [17], although that analysis 
involved unstandardized CXR interpretation methods and CXR 
definitions. In contrast, our findings suggest that hypoxemia, 
tachypnea, crackles, and fever may predict the WHO stand-
ardized definition of CXR consolidation in a study where case 
enrollment used a standardized clinical definition known to 
have high sensitivity but low specificity (Table 2).
We identified substantial differences between sites in the 
distribution of CXR findings (Table  1 and Figure  2). Between 
4% and 20% of CXRs from each site were uninterpretable, and 
Figure 2. Distribution of chest radiograph conclusions by site, for interpretable 
images only (n = 3587). Abbreviation: B, Bangladesh; Both, both consolidation and 
other infiltrate.
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Table 1. Distribution of Signs and Pneumonia Risk Factors by Chest Radiograph Findings Among Children Aged 1–59 Months Hospitalized With World 
Health Organization Defined Severe or Very Severe Pneumonia
All CXRs Abnormal CXRs
N Normal Abnormal P Valuea Any Consolidation Other Infiltrate Only P Valuea
Total (row %) 3587 1652 (46.1) 1935 (53.9) -- 967 (50.0) 968 (50.0) --
Duration of illness (median days 
[interquartile range])
3568 3 (2–4) 3 (2–5) <.001 3 (2–6) 3 (2–5) <.001
Study site (row %) <.001 <.001
Gambia 609 319 (52.4) 290 (47.6) 104 (35.9) 186 (64.1)
Mali 526 273 (51.9) 253 (48.1) 146 (57.7) 107 (42.3)
Zambia HIV− 366 158 (43.2) 208 (56.8) 135 (64.9) 73 (35.1)
Zambia HIV+ 66 8 (12.1) 58 (87.9) 50 (86.2) 8 (13.8)
South Africa HIV− 681 246 (36.1) 435 (63.9) 250 (57.5) 185 (42.5)
South Africa HIV+ 101 12 (11.9) 89 (88.1) 60 (67.4) 29 (32.6)
Kenya 570 286 (50.2) 284 (49.8) 121 (42.6) 163 (57.4)
Thailand 195 96 (49.2) 99 (50.8) 43 (43.4) 56 (56.6)
Bangladesh, Matlab 286 185 (64.7) 101 (35.3) 31 (30.7) 70 (69.3)
Bangladesh, Dhaka 187 69 (36.9) 118 (63.1) 27 (22.9) 91 (77.1)
Clinical and risk factor findings (column %)
Age category, mo .001 <.001
1–5 1414 653 (39.5) 761 (39.3) 417 (43.1) 344 (35.5)
6–11 818 350 (21.2) 468 (24.2) 236 (24.4) 232 (24.0)
12–23 842 375 (22.7) 467 (24.1) 197 (20.4) 270 (27.9)
24–59 513 274 (16.6) 239 (12.4) 117 (12.1) 122 (12.6)
Pneumonia severity .10 <.001
Severe 2483 1121 (67.9) 1362 (70.4) 634 (65.6) 728 (75.2)
Very severe 1104 531 (32.1) 573 (29.6) 333 (34.4) 240 (24.8)
Danger signsb
Head nodding (n = 1103) 570 235 (44.3) 335 (58.5) <.001 209 (62.8) 126 (52.5) .014
Central cyanosis (n = 1103) 71 19 (3.6) 52 (9.1) <.001 27 (8.1) 25 (10.4) .34
Convulsions (n = 1103) 203 145 (27.3) 58 (10.1) <.001 28 (8.4) 30 (12.5) .11
Lethargy (n = 1104) 357 183 (34.5) 174 (30.4) .15 108 (32.4) 66 (27.5) .21
Difficulty feeding (n = 1101) 243 110 (20.8) 133 (23.3) .33 84 (25.3) 49 (20.4) .17
Vomiting (n = 1102) 104 68 (12.9) 36 (6.3) <.001 14 (4.2) 22 (9.2) .016
Other clinical signs and history
HIV positive (n = 1214)c 167 20 (4.7) 147 (18.6) <.001 110 (22.2) 37 (12.5) <.001
Hypoxemia (n = 3577)d 1287 425 (25.8) 862 (44.6) <.001 500 (51.8) 362 (37.4) <.001
Tachypnea (n = 3557)e 2938 1309 (79.7) 1629 (85.1) <.001 827 (86.6) 802 (83.6) .07
Crackles (n = 3569) 2353 1027 (62.3) 1326 (69.0) <.001 647 (67.4) 679 (70.7) .12
Wheeze (n = 3564) 1206 631 (38.3) 575 (30.0) <.001 207 (21.6) 368 (38.4) <.001
Grunting (n = 3568) 598 271 (16.5) 327 (17.0) .67 203 (21.1) 124 (12.9) <.001
Nasal flaring (n = 3581) 2094 887 (53.7) 1207 (62.5) <.001 680 (70.5) 527 (54.6) <.001
Tachycardia (n = 3579)f 1830 818 (49.6) 1012 (52.4) .09 542 (56.2) 470 (48.7) <.001
Temperature ≥38.5°C 637 257 (15.6) 380 (19.6) .001 219 (22.6) 161 (16.6) <.001
Weight-for-age (n = 3574)g <.001 <.001
Normal 2427 1224 (74.3) 1203 (62.5) 569 (59.1) 634 (65.8)
Moderate 635 261 (15.8) 374 (19.4) 186 (19.3) 188 (19.5)
Severe 512 163 (9.9) 349 (18.1) 208 (21.6) 141 (14.6)
Vaccine status (n = 1908)h .91 .20
None 250 120 (13.3) 130 (12.9) 68 (15.0) 62 (11.3)
Complete Hib, no PCV 618 296 (32.7) 322 (32.1) 139 (30.5) 183 (33.3)
Complete PCV 1040 488 (54.0) 552 (55.0) 248 (54.5) 304 (55.4)
Antibiotic pretreatment (n = 3370)i 1356 553 (35.9) 803 (43.9) <.001 456 (49.5) 347 (38.3) <.001
Died within 30 days (n = 3208) 227 73 (4.9) 154 (9.0) <.001 113 (13.5) 41 (4.7) <.001
Restricted to cases with an interpretable chest radiograph finding (n = 3587); for variables missing observations, a total n for that variable is shown in parentheses.
Abbreviations: CXR, chest radiograph; Hib, Haemophilus influenzae type b conjugate vaccine; HIV, human immunodeficiency virus; PCV, Pneumococcal conjugate vaccine.
aPearson χ2 test for all categorical variables. Two-sample t test with equal variances for comparison of means of duration of illness.
bVery severe cases only.
cSouth Africa and Zambia sites only.
dHypoxemia = room air pulse oximetry reading of <90% if at elevation (Zambia and South Africa) or <92% at all other sites. If a room air oxygen saturation reading was not available and the 
child was on supplemental oxygen, they were considered hypoxemic.
eTachypnea = respiratory rate ≥60 breaths per minute if age <2 months, ≥50 if 2–11 months, and ≥40 if 12–59 months.
fTachycardia = heart rate >160 beats per minute (bpm) if age 1–11 months, >150 bpm if 12–35 months, and >140 bpm if 36–59 months.
gWeight-for-age = severe if less than −3 z scores, moderate if between −3 and −2 z scores below WHO median.
hVaccine comparison excludes those children too young (<4 months) to have completed a full biologic course of Hib and/or PCV vaccines, as these children by definition are considered to be 
“unvaccinated” but are not an appropriate comparison group for those who have been vaccinated. Complete vaccination for PCV was defined as 3 or more doses, or 2 doses if there was 
at least 8 weeks between doses and the child was aged <9 months at enrollment or >12 months at the time of the first dose, or 1 or more doses if the age at any of the doses, or age at 
introduction, was ≥24 months. Complete vaccination for Hib conjugate vaccine was defined as 3 or more doses, or 1 or more doses for a child aged >12 months at first dose.
iAntibiotic pretreatment was defined by having either a positive serum bioassay or documented administration of antibiotics on the day of admission at the referral or study hospital prior 
to blood culture collection.
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although we used a more stringent definition of “uninterpret-
able for other infiltrate and/or consolidation” compared to the 
“uninterpretable for consolidation only” definition in most 
applications of the WHO methodology [18], high proportions 
of uninterpretable images highlight the challenges of achieving 
adequate radiographic images in resource-poor settings. The 
proportion of PERCH cases with a finding of consolidation 
(with or without other infiltrate) ranged, by site, from 11% to 
37% in HIV-negative cases. Such differences are consistent with 
findings of consolidation in previous studies of pneumonia. In 
the Gambian pneumococcal conjugate vaccine trial, 17% of hos-
pitalized pneumonia cases in the control arm had consolidation 
in the presence of Hib vaccine [19], while in the Bangladesh Hib 
vaccine case-control study, 26% of all hospitalized pneumonia 
cases, vaccinated and nonvaccinated combined, had consoli-
dation [20]. The proportion of abnormal CXRs (consolidation 
or other infiltrate) among HIV-negative cases also varied by 
site from 35% to 64% (and thus a range of normal CXRs from 
36% to 65%), while 88% of HIV-positive cases had an abnor-
mal CXR in both South Africa and Zambia. The commonly held 
Table 2. Independent Associations Between Chest Radiograph Findings and Clinical Signs, Risk Factors, and Admission Diagnoses Among Children 1–59 
Months of age Hospitalized with WHO Severe and Very Severe Pneumonia
Abnormal vs 
Normal (ref)
Any consolidation 
vs Other infiltrate 
only (ref)
Any consolidation vs 
Normal (ref)
Other infiltrate 
only vs Normal 
(ref)
Adjusted ORa P Value Adjusted ORa P Value Adjusted ORa P Value Adjusted ORa P Value
All cases
Clinical signs
 Hypoxemiab 1.94 <.001 1.13 .30 2.05 <.001 1.84 <.001
 Nasal flaring 1.10 0.24 1.29 .03 1.29 .02 0.97 .74
 Tachypneac 1.40 .001 1.39 .02 1.67 <.001 1.20 .12
 Crackles 1.41 <.001 1.01 .90 1.38 .001 1.39 .001
 Wheeze 0.69 <.001 0.61 <.001 0.52 <.001 0.87 .18
 Temperature ≥38.5℃ 1.41 <.001 1.24 .10 1.60 <.001 1.28 .04
 Grunting 1.07 0.55 1.25 .15 1.14 .34 0.98 .88
 Tachycardiad 1.00 0.99 1.09 .40 1.02 .85 0.96 .64
Admission diagnoses
 Paraffin ingestion 1.34 .69 -- 2.62 .20 --
 Meningitise 0.30 <.001 0.67 .21 0.25 <.001 0.39 <.001
 Sepsis 1.09 .72 1.03 .93 1.12 .70 1.08 .79
 Shockf 1.10 .32 1.29 .04 1.29 .03 0.96 .71
 Bronchiolitis 0.67 <.001 0.72 .04 0.59 <.001 0.78 .07
 Asthma 0.71 .04 0.82 .45 0.63 .05 0.76 .15
 Gastroenteritis 0.59 .003 0.99 .96 0.61 .02 0.59 .02
 Developmental delay 4.32 .001 0.86 .71 4.49 .002 4.79 .001
Very severe cases
Clinical and danger signs 
 Head nodding 0.75 .17 1.68 .06 0.93 .75 0.55 .03
 Central cyanosis 1.55 .16 0.85 .65 1.34 .43 1.67 .18
 Inability to feed/drink 1.00 1.00 1.67 .03 1.25 .27 0.74 .20
 Vomiting 0.66 .12 0.63 .25 0.47 .04 0.79 .47
 Lethargy or unconsciousness 0.98 .93 1.69 .04 1.25 .28 0.76 .21
 Convulsions 0.49 .002 0.86 .67 0.46 .007 0.51 .03
 Hypoxemiab 1.63 .002 1.34 .16 1.79 .002 1.38 .10
 Nasal flaring 1.61 .006 0.98 .95 1.68 .02 1.58 .04
 Tachypneac 1.59 .009 1.45 .17 2.04 .002 1.35 .17
 Crackles 1.95 <.001 1.26 .26 1.96 <.001 1.85 .002
 Wheeze 0.67 .03 0.63 .06 0.56 .008 0.87 .56
 Temperature >38.5℃ 1.24 .23 0.98 .93 1.30 .22 1.26 .30
 Grunting 0.82 .31 1.01 .97 0.82 .40 0.84 .47
 Tachycardiad 1.33 .05 1.38 .10 1.46 .03 1.15 .42
Abbreviations: OR, Odds ratio; WHO, World Health Organization.
aWithin each of the three models (clinical signs; admission diagnoses; and danger signs and clinical signs among cases with very severe pneumonia), all indicated variables were included, 
regardless of univariate significance.  The three models were developed to examine clinical characteristics with likely collinearity.  Models are adjusted for age (in months), site (not strati-
fied for HIV status), severity (‘All Cases’ models only), and HIV status; ‘no’ is the reference category for all variables.
bHypoxemia=room air pulse-oximetry reading of <90% if at elevation (Zambia and South Africa) or <92% at all other sites. If a room air oxygen saturation reading was not available and 
the child was on supplemental oxygen they were also considered hypoxemic.
cTachypnea=respiratory rate ≥60 breaths per minute if age <2 months, ≥50 if 2-11 months, and ≥40 if 12-59 months.
dTachycardia=heart rate >160 beats per minute (bpm) if age 1-11 months, >150 bpm if 12-35 months, and >140 bpm if 36-59 months.
eMeningitis defined as an admission diagnosis of meningitis or a bulging fontanelle if age <18 months.
fShock defined as capillary refill time of >3sec, or cool peripheries, or weak pulse with tachycardia.
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understanding is that etiology, severity, duration of infection, 
and host immune reaction are major predictors of CXR find-
ings [21–23]. If this is true, observed differences in the distribu-
tions of CXR findings between sites likely reflect determinants 
of those CXR predictors, such as healthcare-seeking behaviors, 
availability of antibiotics, and environmental and living con-
ditions. Epidemiologic studies that use CXR case definitions 
should recognize that differences between studies could reflect 
not only differences in pneumonia etiology but also variables 
that alter the timing of care seeking or host response to infection.
Age has an important interaction with CXR results and severity, 
as expected (Supplemental Table 1). Danger signs, which are not 
specific for respiratory disease, were more indicative of an abnor-
mal CXR in younger children; we observed that among very severe 
cases, the youngest children (aged 1–5 months) were more likely 
to have an abnormal CXR than older children. However, more 
specific pneumonia findings (such as lower chest wall indrawing) 
are less associated with pneumonia in younger children because 
the physiologic compliance of the lower chest makes this finding 
more common in a variety of illnesses. Thus, among severe cases, 
we observed that an abnormal CXR was less likely among the 
youngest children compared to those in other age groups. These 
findings suggest that danger signs may not be useful criteria for 
diagnosing pneumonia in children aged >6 months, particularly 
in pneumonia studies where a low proportion of false positives is 
important. However, danger signs remain useful for bacterial treat-
ment algorithms, since they will identify nonpneumonia cases that 
nevertheless require treatment.
We observed significant differences in case fatality ratios 
among HIV-negative cases depending on their CXR findings; 
those with consolidation on CXR were at significantly higher 
risk of death than those with a normal CXR or with other infil-
trates only. The presence of other infiltrates did not alter the risk 
of death compared to a normal CXR appearance in children 
with severe or very severe pneumonia. This likely reflects the 
association between consolidation and bacterial pneumonia 
and the tendency for bacterial pneumonia to be more severe 
than viral pneumonia. An association between a CXR finding 
of “dense infiltrates” and mortality has also been documented in 
the Philippines [24]; in Fiji, CXR consolidation had a case fatal-
ity ratio of 6.8% using the WHO methodology [25]. Our find-
ings are limited in that 100 cases who died were missing a CXR, 
the majority (92%) because death occurred before this could 
be obtained. If the distribution of CXR findings in these cases 
differed from the other cases who died, the difference in case 
fatality ratios may either be underestimated or overestimated. 
Nonetheless, these findings suggest that in order to further 
reduce the mortality burden of pneumonia, a focus on groups 
with a high prevalence of consolidation should be a priority.
Our findings have important methodological limitations. First, 
without a gold standard for pneumonia diagnosis, clinical signs 
and radiological findings may be correlated to each other without 
being correlated to true pneumonia. Second, if observers record-
ing clinical signs were aware of a case’s CXR appearance, the 
independence of these measurements may be violated. Third, our 
definition of hypoxemia included those on supplemental oxygen, 
Table 3. Case Fatality Ratios by Chest Radiograph Findings for Cases with Known Survival Status at 30 Days Post Dischargea
Total Cases (N) and Case Fatality Ratio (%)
Chest radiograph finding
Total 
Deaths
All sites Gambia Mali Zambia
South 
Africa Kenya Thailand Matlab Dhaka
N % N % N % N % N % N % N % N % N %
Overalla
Interpretable 227 3208 7.1 580 4.5 510 12.4 246 24.0 661 5.6 555 5.4 190 4.7 282 0.4 184 1.1
Abnormal 154 1711 9.0 279 5.7 245 15.1 159 26.4 436 7.8 278 6.5 98 5.1 100 1.0 116 0.9
Normal 73 1497 4.9 301 3.3 265 9.8 87 19.5 225 1.3 277 4.3 92 4.4 182 0.0 68 1.5
Any consolidation 113 837 13.5 102 8.8 142 19.7 117 29.1 258 9.3 119 10.9 42 9.5 31 0.0 26 3.9
Other infiltrate only 41 874 4.7 177 4.0 103 8.7 42 19.1 178 5.6 159 3.1 56 1.8 69 1.4 90 0.0
Uninterpretable 46 329 14.0 27 0.0 67 19.4 64 34.4 89 9.0 26 7.7 9 0.0 38 2.6 9 0.0
Missing 100 231 43.3 2 50.0 77 57.1 59 74.6 35 11.4 35 17.1 20 0.0 1 0.0 2 50.0
HIV negativeb
Abnormal 118 1582 7.5 -- -- 125 20.0 359 5.3 -- -- -- --
Normal 66 1474 4.5 -- -- 81 17.3 214 0.0 -- -- -- --
Any consolidation 85 739 11.5 -- -- 87 21.8 205 6.8 -- -- -- --
Other infiltrate only 33 843 3.9 -- -- 38 15.8 154 3.3 -- -- -- --
HIV positiveb
Abnormal 36 129 27.9 -- -- 34 50.0 77 19.5 -- -- -- --
Normal 7 23 30.4 -- -- 6 50.0 11 27.3 -- -- -- --
Any consolidation 28 98 28.6 -- -- 30 50.0 53 18.9 -- -- -- --
Other infiltrate only 8 31 25.8 -- -- 4 50.0 24 20.8 -- -- -- --
Abbreviation: HIV, human immunodeficiency virus. 
aCases with unknown 30-day survival (n=464) are omitted from this analysis.
bSite-specific HIV analyses are restricted to sites with high prevalence only (South Africa and Zambia).
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which may not reliably indicate true hypoxemia on admission. 
Finally, our study was not designed to assess the relationship 
between duration of illness and abnormal CXR findings, yet this 
is likely to have a strong influence on CXR positivity.
In summary, the WHO clinical pneumonia definitions were 
designed as a sensitive tool for the management of pneumonia 
cases. Our experience suggests that almost half of these cases do 
not have radiological evidence of pneumonia. Chest radiography 
continues to be a valuable method for case identification that is 
correlated to clinical signs of pneumonia and can be applied to 
a variety of pneumonia studies, including etiology studies. Yet, 
radiologic findings in cases of clinical pneumonia likely reflect 
a complex mix of etiology, healthcare-seeking patterns, antibi-
otic use, age, and underlying health conditions such as HIV and 
malnutrition.
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